Currently, adult AML patients with DNMT3A mutation are usually treated with a combination of daunorubicin, a DNA damaging anthracycline drug and cytarabine, a DNA damaging antimetabolic agent8,9. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.